Redwood City, CA – According to filings with the U.S. Securities and Exchange Commission, Kriya Therapeutics is raising $99,999,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shankar Ramaswamy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kriya Therapeutics
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed and manufactured improving speed to market and delivering significant reductions in the cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE). The company is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic diseases. With locations in Silicon Valley, Calif., and Research Triangle Park, N.C., Kriya was founded by pioneers in the biopharmaceutical industry and is backed by blue-chip life sciences and technology investors.

To learn more about Kriya Therapeutics, visit http://kriyatherapeutics.com/

Contact:
Shankar Ramaswamy, Chief Executive Officer
833-574-9289
sramaswamy@kriyatherapeutics.com
https://www.linkedin.com/in/shankar-ramaswamy-m-d-8334959/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved